UTJMS 2026 February 16, 15(S1):e1-e3 doi:10.46570/utjms-2026-1674

MDMA-Assisted Therapy for PTSD: Neuroplastic Change or Psychotherapeutic Catalyst?

Aidan R. Butler[1], **Robert E. McCullumsmith**[1,2*]

[1]University of Toledo Department of Neurosciences and Psychiatry University of Toledo College of Medicine and Life Sciences

[2]Neurosciences institute, ProMedica, Toledo, Ohio

Email: robert.mccullumsmith@utoledo.edu

Received 8/1/2025

Accepted for publication 10/18/2025

Published 2/16/2026

Abstract

MDMA-assisted psychotherapy has emerged as a promising treatment for post-traumatic stress disorder (PTSD), particularly in individuals unresponsive to conventional interventions such as SSRIs and trauma-focused cognitive behavioral therapy. As recent clinical trials report durable symptom remission, ongoing debate surrounds the mechanisms underlying its therapeutic effects. This review explores two major frameworks: a neurobiological model proposing that MDMA supports trauma reprocessing through fear extinction, memory reconsolidation, and neuroplasticity, and a relational model highlighting MDMA's prosocial and empathogenic properties that enhance therapeutic alliance and suggestibility. Evidence from both human and rodent studies indicates that MDMA reduces amygdala reactivity, increases hippocampal connectivity, and modulates serotonergic and oxytocinergic signaling. Concurrently, clinical findings suggest that the quality of the therapeutic relationship plays a critical role in treatment outcomes. Rather than viewing these processes as mutually exclusive, we propose a synergistic model in which MDMA creates a "window of emotional safety" that allows for both neurobiological and interpersonal mechanisms to support healing. Understanding this dual-action model is essential for refining treatment protocols, improving therapist training, and guiding future research in psychedelic-assisted psychotherapy.

Keywords: MDMA-assisted psychotherapy, Post-Traumatic Stress Disorder, Therapeutic Mechanisms

UTJMS 2026 February 16, 15(S1):e1-e3 doi:10.46570/utjms-2026-1674

1. Introduction

MDMA-assisted psychotherapy has gained traction as a novel treatment for post-traumatic stress disorder (PTSD). For patients unresponsive to conventional approaches such as selective serotonin reuptake inhibitors (SSRIs) and trauma-focused cognitive behavioral therapy (CBT). Clinical trials, studying MDMA-assisted psychotherapy, report robust and sustained symptom relief, prompting interest in its broader integration into psychiatric care (1). Yet, as implementation approaches, a central question remains: how exactly does MDMA work as a therapeutic agent? Two primary mechanisms have been proposed. The first emphasizes trauma reprocessing, suggesting that MDMA facilitates fear extinction and disrupts the reconsolidation of traumatic memories. Studies using both human and rodent models show that MDMA reduces amygdala reactivity, enhances emotional memory network connectivity, and supports neuroplasticity through serotonin, oxytocin, and brain-derived neurotrophic factor (BDNF) signaling (2-7). The second theory focuses on enhanced therapeutic alliance, arguing that MDMA's prosocial effects may amplify important psychotherapy factors such as trust, openness, and the therapist-client relationship (1, 8-10). This review aims to examine the evidence for each mechanism and reflect on how these models might shape future therapeutic interventions and psychiatric education.

2. Discussion

The growing success of MDMA-assisted therapy in clinical trials has increased interest in understanding how this treatment works, a question with direct implications for clinical practice, training, and patient selection. Two frameworks dominate the current discourse: one neurobiological and memory-centered, the other relational and context-driven.

Support for the trauma reprocessing model comes from animal studies and human neuroimaging. MDMA dampens amygdala activity, increases hippocampal engagement, and facilitates synaptic plasticity (2). These conditions may promote fear extinction and allow for reprocessing of traumatic memories in a safer state (2-7). This view aligns with traditional exposure-based therapies and suggests MDMA augments existing paradigms by making recall of the trauma more tolerable and flexible for the patient.

In contrast, growing attention is being paid to common factors in psychotherapy, especially the role of the therapeutic alliance. One study found that strength of the therapeutic alliance predicted PTSD symptom improvement, regardless of trauma-specific content (8). MDMA's effects on oxytocin and serotonin systems may heighten openness and suggestibility, increasing responsiveness to therapist input (1, 10). This model does not deny the importance of memory but instead frames MDMA as a tool that amplifies the relational environment in which the therapy occurs.

Rather than seeing these mechanisms as mutually exclusive, a more integrative view may be warranted. An interesting hypothesis suggests that MDMA appears to open a "window of emotional safety" that supports both trauma processing and therapeutic connection (4). This dual-action hypothesis suggests that effectiveness may depend on how the therapy is delivered: a strong therapeutic relationship may be necessary to guide trauma work, while the pharmacologic effects lower barriers to engagement.

Understanding these pathways matters for academic clarity, as well as for practical implementation. If trauma reprocessing is central, protocols for treatment may prioritize structured memory exposure. If alliance and context dominate, therapist training, setting, and integration practices become more critical. Future research should aim to disentangle these mechanisms in diverse populations and settings, using both qualitative and biological measures.

3. Conclusion

To guide clinical practice and training, understanding the mechanisms of MDMA-assisted psychotherapy is key. The existing evidence points to dual action: promoting neurobiological conditions for trauma reprocessing and enhancing the therapeutic relationship. In doing so, MDMA challenges the traditional boundaries between split pharmacology and psychotherapy treatments. Effective use of MDMA therapy requires attention to both its neural effects and the quality of the therapist–patient relationship.

UTJMS 2026 February 16, 15(S1):e1-e3 doi:10.46570/utjms-2026-1674

References

1. O'Donnell, K.C., et al., *The conceptual framework for the therapeutic approach used in phase 3 trials of MDMA-assisted therapy for PTSD.* Front Psychol, 2024. **15**: p. 1427531.

2. Feduccia, A.A. and M.C. Mithoefer, *MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?* Prog Neuropsychopharmacol Biol Psychiatry, 2018. **84**(Pt A): p. 221–228.

3. Sottile, R.J. and T. Vida, *A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy.* Front Psychiatry, 2022. **13**: p. 991753.

4. Singleton, S.P., et al., *Altered brain activity and functional connectivity after MDMA-assisted therapy for post-traumatic stress disorder.* Front Psychiatry, 2022. **13**: p. 947622.

5. Sarmanlu, M., et al., *MDMA-assisted psychotherapy for PTSD: Growing evidence for memory effects mediating treatment efficacy.* Prog Neuropsychopharmacol Biol Psychiatry, 2024. **128**: p. 110843.

6. Zhang, X., et al., *Negative Affect Circuit Subtypes and Neural, Behavioral, and Affective Responses to MDMA: A Randomized Clinical Trial.* JAMA Netw Open, 2025. **8**(4): p. e257803.

7. Avgana, H., R.S. Toledano, and I. Akirav, *Examining the Role of Oxytocinergic Signaling and Neuroinflammatory Markers in the Therapeutic Effects of MDMA in a Rat Model for PTSD.* Pharmaceuticals (Basel), 2024. **17**(7).

8. Zeifman, R.J., et al., *Preliminary evidence for the importance of therapeutic alliance in MDMA-assisted psychotherapy for posttraumatic stress disorder.* Eur J Psychotraumatol, 2024. **15**(1): p. 2297536.

9. Lewis, B.R. and K. Byrne, *A Review of MDMA-Assisted Therapy for Posttraumatic Stress Disorder.* Focus (Am Psychiatr Publ), 2023. **21**(3): p. 247–256.

10. Shannon, S. and J. Geller, *MDMA for PTSD and beyond: a new paradigm brings hope.* Front Hum Neurosci, 2024. **18**: p. 1475013.

